A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study

Figures & data

Table 1 Comparison of oncology drug/indication combinations approved by Food and Drug Administration and Health Canada requiring Canada

Table 2 Difference in dates of marketing approval and decisions about drug/indication between Canada and the United States

Availability of data and materials

All the data is included in the manuscript.